drugset
drugset / Trial / NCT00519389

Safety, Reactogenicity and Immunogenicity of an H5N1 VLP

NCT00519389 ↗

Phase 1/2 Completed 230 enrolled Novavax
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, reactogenicity, and immunogenicity of 3 potencies (dosages) of H5N1 VLP vaccine or placebo in healthy adults 18 to 40 years of age.

Timeline

Start
2007-07
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject H5N1 VLP Vaccine Vaccine — —

Indications

influenza